FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

By Pacini P.   Rinaldini M.   Algeri R.   Guarneri A.   Tucci E.   Barsanti G.   Neri B.   Bastiani P.   Marzano S.   Fallai C.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 966-975

Elsevier

Access to resources Recommend Favorite

Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin

By  

Oncology Reports, Vol. 33, Iss. 2, 2015-01 ,pp. : 721-728

Spandidos Publications

Access to resources Recommend Favorite

Inhibition of Telomerase Activity by Cisplatin in Human Testicular Cancer Cells

By Burger A.M.   Double J.A.   Newell D.R.  

European Journal of Cancer, Vol. 33, Iss. 4, 1997-04 ,pp. : 638-644

Elsevier

Access to resources Recommend Favorite

Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: ^{31}P and ^{13}C nuclear magnetic resonance studies

By Vivi A.  

Breast Cancer Research and Treatment, Vol. 43, Iss. 1, 1997-03 ,pp. : 15-25

Springer Publishing Company

Access to resources Recommend Favorite

Combined effect of papuamine and doxorubicin in human breast cancer MCF7 cells

By                

Oncology Letters, Vol. 8, Iss. 2, 2014-01 ,pp. : 547-550

Spandidos Publications

Access to resources Recommend Favorite